Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy R D J Radstake

Showing results (21-30 of 236) with videos related to

Pageof 24
Sort By:
Annals of the Rheumatic Diseases|December 11, 2013
Targeting Th2-typified immune responses to prevent immunopathology in rheumatic diseases: belittled therapeutic strategies?Frederique M Moret, Timothy R D J Radstake, Joel A G van Roon
Expert Review of Clinical Immunology|November 13, 2013
Accelerated telomere shortening in rheumatic diseases: cause or consequence?Amina Z A Dehbi, Timothy R D J Radstake, Jasper C A Broen
Arthritis and Rheumatism|May 14, 2013
Editorial: interleukin-7 and its receptor: the axis of evil to target in Sjögren's syndrome?Joel A G van Roon, Aike A Kruize, Timothy R D J Radstake
Arthritis & Rheumatology (Hoboken, N.J.)|February 21, 2017
Review: Innate Lymphoid Cells: Sparking Inflammatory Rheumatic Disease?Mark H Wenink, Emmerik F A Leijten, Tom Cupedo, et al.
Current Drug Targets|June 14, 2017
Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease?Mark Schuiveling, Nadia Vazirpanah, Timothy R D J Radstake, et al.
Rheumatology (Oxford, England)|July 12, 2015
Thymic stromal lymphopoietin as a novel mediator amplifying immunopathology in rheumatic diseaseMaarten R Hillen, Timothy R D J Radstake, Cornelis E Hack, et al.
Clinical Reviews in Allergy & Immunology|September 4, 2017
Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's PerspectiveMarta Cossu, Lorenzo Beretta, Petra Mosterman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 1, 2017
Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the SerumMarta Cossu, Lenny van Bon, Carlo Preti, et al.
Rheumatology (Oxford, England)|August 16, 2020
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazineMarleen E Jacobs, Juliëtte N Pouw, Paco Welsing, et al.
Molecular Immunology|September 14, 2019
CXCL4 is a driver of cytokine mRNA stability in monocyte-derived dendritic cellsSandra C Silva-Cardoso, Cornelis P J Bekker, Marianne Boes, et al.
Pageof 24

Showing results (21-30 of 236) with videos related to

Sort By:
Pageof 24
Annals of the Rheumatic Diseases|December 11, 2013
Targeting Th2-typified immune responses to prevent immunopathology in rheumatic diseases: belittled therapeutic strategies?Frederique M Moret, Timothy R D J Radstake, Joel A G van Roon
Expert Review of Clinical Immunology|November 13, 2013
Accelerated telomere shortening in rheumatic diseases: cause or consequence?Amina Z A Dehbi, Timothy R D J Radstake, Jasper C A Broen
Arthritis and Rheumatism|May 14, 2013
Editorial: interleukin-7 and its receptor: the axis of evil to target in Sjögren's syndrome?Joel A G van Roon, Aike A Kruize, Timothy R D J Radstake
Arthritis & Rheumatology (Hoboken, N.J.)|February 21, 2017
Review: Innate Lymphoid Cells: Sparking Inflammatory Rheumatic Disease?Mark H Wenink, Emmerik F A Leijten, Tom Cupedo, et al.
Current Drug Targets|June 14, 2017
Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease?Mark Schuiveling, Nadia Vazirpanah, Timothy R D J Radstake, et al.
Rheumatology (Oxford, England)|July 12, 2015
Thymic stromal lymphopoietin as a novel mediator amplifying immunopathology in rheumatic diseaseMaarten R Hillen, Timothy R D J Radstake, Cornelis E Hack, et al.
Clinical Reviews in Allergy & Immunology|September 4, 2017
Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's PerspectiveMarta Cossu, Lorenzo Beretta, Petra Mosterman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 1, 2017
Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the SerumMarta Cossu, Lenny van Bon, Carlo Preti, et al.
Rheumatology (Oxford, England)|August 16, 2020
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazineMarleen E Jacobs, Juliëtte N Pouw, Paco Welsing, et al.
Molecular Immunology|September 14, 2019
CXCL4 is a driver of cytokine mRNA stability in monocyte-derived dendritic cellsSandra C Silva-Cardoso, Cornelis P J Bekker, Marianne Boes, et al.
Pageof 24